Weekly Dose of Optimism #190

· ai-agents · Source ↗

TLDR

  • Pancreatic cancer mRNA vaccine shows 87.5% six-year survival in responders; SpaceX optioned Cursor for $60B; Fervo Energy filed S-1; cabless autonomous truck debuts.

Key Takeaways

  • BioNTech/Genentech’s personalized mRNA vaccine (autogene cevumeran) produced T-cell responses in 8 of 16 Phase 1 patients; 7 of those 8 are alive six years out.
  • SpaceX agreed to a $10B option to acquire Cursor at $60B post-IPO, pairing Cursor’s coding models with SpaceX/xAI’s compute infrastructure.
  • Fervo Energy filed an S-1 targeting Nasdaq (FRVO), with 3.65 GW of geothermal capacity in development; Cape Station targets $7,000/kW, with a goal of $3,000/kW.
  • Humble launched out of stealth with $24M seed to build a cabless autonomous truck designed from scratch for intermodal containers, not retrofitted from human-driver architecture.
  • Medra opened a 38,000 sq ft SF lab with ~100 robotic arms running biology experiments 24/7, claiming to push automatable bio-tech tasks from 5% to 75%.

Why It Matters

  • The pancreatic cancer trial is only 16 patients with no randomization, but 85% T-cell memory persistence through chemotherapy challenges the prior assumption that pancreatic tumors are immunologically unreachable.
  • Fervo’s S-1 and Humble’s design-from-scratch approach both reflect the same pattern: replacing inherited constraints (fossil fuel drilling assumptions, human-cab truck geometry) with purpose-built alternatives.
  • Medra’s robot arms operate standard human-scale lab instruments via computer vision rather than requiring API-native equipment, which is the practical bottleneck most prior lab automation failed to clear.

Packy McCormick, Not Boring · 2026-04-24 · Read the original